Europe - France

1

Industry focus: Healthcare and life sciences

McDermott Will & Emery AARPI

More informationMore information

The ‘competent, trustworthy’ team at McDermott Will & Emery AARPI leverages the firm’s international network to act for a lucrative client base of medical device manufacturers, digital health companies, and investment funds. The group is particularly adept at advising on licensing agreements and partnerships, M&A, and the IP aspects of transactions. Practice head Emmanuelle Trombe is noted for her expansive transactional expertise, regularly advising both French and American biopharma and medical device clients on divestitures and joint ventures. Anthony Paronneau has deep knowledge spanning a broad range of commercial matters, including series funding rounds, fundraisings within the biotech sector, and strategic alliances.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘A competent, trustworthy team that is fully available at any time.’

  • ‘Anthony Paronneau has great availability, understanding of the field and the issues, advice and confidence.’

  • ‘Excellent knowledge of the needs of a biotech throughout its lifecycle. Ability to find solutions.’

Key clients

  • Pierre Fabre
  • Novo Holdings A/S
  • Corteria Pharmaceuticals
  • Biocorp Production SA
  • Innate Pharma S.A.
  • TreeFrog Therapeutics
  • Smart Immune
  • DiogenX
  • Five Arrows Principal Investments
  • Porsolt SAS
  • DBV Technologies
  • Owkin
  • TRiCares
  • Cousin Surgery
  • Dynacure SAS
  • Newton Biocapital
  • TransCure bioServices
  • Relyens Innovation Santé /Turenne Capitaland UI Investissement
  • Quantis AG

Work highlights

  • Advised Pierre Fabre on the negotiation and conclusion of a collaboration and license agreement with Scorpion Therapeutics to co-develop two next-generation epidermal growth factor receptor (EGFR) inhibitors.
  • Advised Novo Holdings A/S, as well as the other historical investors, on a 130 €M Series C investment in Amolyt Pharma (a clinical stage biotechnology company).
  • Advised Five Arrows Principal Investments on the sale of Hygie31, a major player in the health and wellness sector, to Latour Capital and Bpifrance as minority shareholder.

Lawyers

Leading individuals

Anthony Paronneau

Anthony Paronneau

McDermott Will & Emery LLP

Anthony Paronneau is a partner, he advises clients on all aspects of corporate and business law, with a particular focus on pharmaceutical, medical device, biotech and health care industries. Anthony has significant experience advising life sciences companies, private equity funds and venture capital firms on a number of merger and acquisition (M&A) and private equity transactions, including acquisitions, financing rounds, joint ventures and divestitures. He also regularly advises life sciences companies on collaborations, licensing and distribution arrangements. For further details of Anthony's biography, please view McDermott website here.

Emmanuelle Trombe

Emmanuelle Trombe

McDermott Will & Emery LLP

Partner Emmanuelle Trombe represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerings, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities. For further details of Emmanuelle's biography, please view McDermott website here.

Practice head

The lawyer(s) leading their teams.

Emmanuelle Trombe

Other key lawyers

Anthony Paronneau, Anne-France Moreau

© 2024 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 2423756 VAT 324572722

Registered address: 188 Fleet Street, London, EC4A 2AG